Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Example systems, methods and machine readable storage media to facilitate locking medical exams in a healthcare system are disclosed herein. An example method for locking a medical exam in a workflow queue for a clinical user includes authenticating the clinical user during a user session. The example method also includes obtaining a user selection of the medical exam in the workflow queue during the user session. The example method also includes associating a permission level to a session user identifier associated with the user session. The example method also includes determining whether the permission level includes clearance to lock the medical exam, and, in response to determining that the permission level includes clearance to lock the medical exam, flagging the medical exam as read-only, wherein the flagged medical exam remains flagged after the clinical user ends the user session.

Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Abstract: Automatic swimming pool cleaners are detailed. The cleaners may employ filter bags with novel stiffeners to help retain their optimal debris-collection shapes in use. They additionally may include bags made of material having sanitizing properties or additives, allowing water sanitization to occur as water flows through the bags themselves. Cleaners described herein further may include discs having generally radial but non-linear slits to facilitate navigation in particular conditions and fix buoyant material within a collar by which a bag is attached to a body of the device.

Abstract: This invention relates to inhibiting 11?HSD1.

Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Abstract: This invention relates to inhibiting 11?HSD1.

Abstract: Automatic swimming pool cleaners are detailed. The cleaners may employ filter bags with novel stiffeners to help retain their optimal debris-collection shapes in use. They additionally may include bags made of material having sanitizing properties or additives, allowing water sanitization to occur as water flows through the bags themselves. Cleaners described herein further may include discs having generally radial but non-linear slits to facilitate navigation in particular conditions and fix buoyant material within a collar by which a bag is attached to a body of the device.

Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

Abstract: A skateboard comprises a riding platform pivotably mounted to a substantially rigid chassis. The chassis mounts a plurality of wheels arranged in two substantially in-line rows. Embodiments have respectively four and five wheels in each row to redundantly support the weight of the rider. The advantages of the in-line roller skate are thus realized in this skateboard. The steerable wheels are mounted on bearings to individual wheel housings. The wheel housings are rotatably mounted within the chassis to allow steering. The housings are steered by a network of links within the chassis. Steering input to the linkage within the chassis originates from tilting of the riding platform from side to side. A steering arm mounted on the riding platform extends downward into the chassis engaging the steering linkage. A foot operated sliding actuator mounted on the top of the riding platform varies the angle of engagement of the steering arm with the steering linkage.